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Our recent clinical trial has shown that erythropoietin 
(EPO) therapy signiﬁ  cantly increased circulating endo-
thelial progenitor cell (EPC) levels and was strongly 
associated with favorable 90-day clinical outcomes after 
ischemic stroke (IS) [1]. Contrary to the ﬁ  ndings of our 
study [1] and of others [2,3], the randomized phase II/III 
German Multicenter EPO Stroke Trial [4], which is 
currently the largest clinical study on EPO treatment in 
patients with IS, not only failed to show any additional 
beneﬁ  t but also demonstrated increased mortality after 
combined therapy with EPO and tissue plasminogen 
activator (tPA) [4]. Interestingly, subgroup analysis of the 
study revealed that EPO therapy improved 90-day clinical 
outcome in patients without additional tPA therapy [4]. 
In this way, the ﬁ  ndings from the subgroup analysis of 
that study [4] corroborate those of our clinical trial [1].
We thank Minnerup and colleagues [5] for their 
comments in the previous issue of Critical Care. Th  ese 
authors suggested that, for evaluating 90-day neurological 
outcome, the modiﬁ  ed Rankin Scale or the Barthel Index 
could be superior to the National Institutes of Health 
Stroke Scale (NIHSS) that was used in our study [5]. Th  ey 
also mentioned that, when the components of the 
composite endpoint in our study protocol are considered, 
the signiﬁ   cantly higher number of patients with an 
NIHSS score of at least 8 after placebo treatment is also 
likely to be caused by the high rate of recurrent strokes 
and does not necessarily reﬂ  ect improved neurological 
function in the EPO group [5]. However, NIHSS is widely 
accepted as one of the most eﬃ   cacious tools for evalu-
ating neurological outcome after acute IS. Additionally, 
the trial in our study was prospective, randomized, and 
placebo-controlled – this is the best design to minimize 
the selection bias between the study group and the 
control group. Accordingly, we suggest that the signiﬁ  -
cantly lower number of patients with an NIHSS score of 
at least 8 in the EPO group in comparison with the 
placebo group could reﬂ   ect simply the therapeutic 
beneﬁ  t of EPO therapy in improving the 90-day neuro-
logical outcome rather than a mere speculation of a 
higher rate of recur  rent strokes in the placebo group.
Th   e optimal dosage of EPO and duration of treatment 
for patients after IS remain uncertain. Th   is may account
for some inconsistency in improvement of neurological 
outcome after IS in clinical trials [1-4]. Accordingly, we 
disagree with Minnerup and colleagues [5] that ‘the 
potential side eﬀ   ects and the failed eﬃ   cacy  in  large 
clinical trials will presumably prevent the use of EPO as a 
therapy to increase EPCs after stroke’.
Minnerup and colleagues also underscored that the 
study was ﬁ   rst assigned to a trial register (ISRCTN 
96340690) in January 2011, which was 10 months after 
the inclusion of the last patients in March 2010 [5]. We 
would like to underscore that, in addition to receiving 
institutional review board approval, our study [1] was 
reviewed and approved by the National Science Council 
of Taiwan before implementation. Actually, our clinical 
trial started long before we applied for an assignment to a 
trial registry. We believe that well-controlled studies 
remain the primary bases of scientiﬁ  c progress. Further 
evidence is required for solid conclusions to be made.
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